These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 22357809)
41. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Phanuphak N; Ananworanich J; Teeratakulpisarn N; Jadwattanakul T; Kerr SJ; Chomchey N; Hongchookiat P; Mathajittiphun P; Pinyakorn S; Rungrojrat P; Praihirunyakit P; Gerschenson M; Phanuphak P; Valcour V; Kim JH; Shikuma C; Antivir Ther; 2012; 17(8):1521-31. PubMed ID: 23220732 [TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715 [TBL] [Abstract][Full Text] [Related]
43. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Sax PE AIDS; 2012 Jul; 26(11):1371-85. PubMed ID: 22546988 [TBL] [Abstract][Full Text] [Related]
44. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698 [TBL] [Abstract][Full Text] [Related]
45. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. Chi BH; Chintu N; Cantrell RA; Kankasa C; Kruse G; Mbewe F; Sinkala M; Smith PJ; Stringer EM; Stringer JS J Acquir Immune Defic Syndr; 2008 Jun; 48(2):220-3. PubMed ID: 18520682 [TBL] [Abstract][Full Text] [Related]
46. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes. Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066 [TBL] [Abstract][Full Text] [Related]
47. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298 [TBL] [Abstract][Full Text] [Related]
48. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332 [TBL] [Abstract][Full Text] [Related]
49. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Smith DE; Chan DJ; Maruszak H; Jeganathan S Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757 [TBL] [Abstract][Full Text] [Related]
51. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China. Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847 [TBL] [Abstract][Full Text] [Related]
52. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933 [TBL] [Abstract][Full Text] [Related]
53. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD Retrovirology; 2009 May; 6():44. PubMed ID: 19439089 [TBL] [Abstract][Full Text] [Related]
54. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study. Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG; PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892 [TBL] [Abstract][Full Text] [Related]
56. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. Labarga P; Medrano J; Seclen E; Poveda E; Rodriguez-Novoa S; Morello J; de Mendoza C; Vispo E; Soriano V AIDS; 2010 Mar; 24(5):777-9. PubMed ID: 20168201 [TBL] [Abstract][Full Text] [Related]
58. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD. Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856 [TBL] [Abstract][Full Text] [Related]
59. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. Zash R; Souda S; Chen JY; Binda K; Dryden-Peterson S; Lockman S; Mmalane M; Makhema J; Essex M; Shapiro R J Acquir Immune Defic Syndr; 2016 Apr; 71(4):428-36. PubMed ID: 26379069 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]